Utilize cutting-edge technologies to create neoantigen-based therapeutics for cancer patients.
PepGene is an immuno-oncology company using novel computational algorithms and drug delivery technology to create personalized, neoantigen-based therapeutics. Motivated by a wide range of unmet needs in cancer treatment, PepGene combines AI algorithms with novel neoantigen sources and novel vaccine delivery system to create highly-personalized, low-risk cancer vaccines that can activate the human immune system to efficiently eradicate cancer cells while minimizing the potential of side effects.
Although existing target and immune-oncology therapies have significantly improved the cancer patient clinical outcome, a large portion of cancer patients do not respond to any types of clinical treatments and are in desperate need of novel therapies.
Inspired by the true potential of personalized cancer medicine that utilizes the unique neoantigen profile of each cancer patients, PepGene is dedicated to using cutting-edge technologies to create neoantigen-based therapeutics that can significantly increase the specificity of cancer immunotherapy treatment and improve the life quality of cancer patients.
Our cofounders are experienced entrepreneurs and professionals from world-leading cancer research institutions and pharmaceutical companies, including MIT, Swiss EPHL, MD Anderson Cancer Center, and Sanofi.
Combine novel computational algorithms and drug delivery technology to create neoantigen-based therapeutics that can empower human immune system to efficiently eradicate cancer cells and improve the lives of cancer patients.
Translate science from bench to bedside to develop personalized cancer therapy that dramatically improves the clinical outcome of cancer patients.